Phase II DORA Study of Olaparib With or Without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38236575/
PFS was longer than expected with both regimens. A patient subset with wild-type BRCA platinum-sensitive aTNBC had durable disease control with chemotherapy-free maintenance.
At 9.8 months of median follow-up, median PFS rates from randomization were 4.0 months with olaparib and 6.1 months with combination treatment, both of which were significantly longer than the historical control treatment.
-
Albert Dekker1yrit is great but presence of other mutations and correlation with and against HRD is not addressed here.
Association of Fibroids, Endometriosis, and Gynecologic Surgeries With Breast Cancer Incidence and Hormone Receptor Subtypes
Source : https://pubmed.ncbi.nlm.nih.gov/38260971/
Fibroids and endometriosis are sex hormone-mediated and exhibit cancer-like behavior. Breast cancer may be more common in women who have had these conditions, but the literature is conflicting and does...
Researchers observed a modest positive association between fibroids and breast cancer, particularly ER-positive breast cancer. No relationship with endometriosis and breast cancer incidence was found.
-
Albert Dekker1yrunfortunately label is very limited and does not address hormonal sensitivity
Real-World Use of Multigene Signatures in Early Breast Cancer: Differences to Clinical Trials
Source : https://pubmed.ncbi.nlm.nih.gov/38265569/
In this real-world series, Oncotype DX was the test almost exclusively used. Despite reimbursement being linked to pre-test chemotherapy recommendation, almost 3/4 patients resulted in the low-RS group. The significant...
Despite reimbursement being linked to pre-test chemotherapy recommendation, almost 75% of patients resulted in the low-RS group.
Adjuvant Treatment in Hormone Receptor-Positive Early Breast Cancer: New Approaches of Endocrine Therapy
Source : https://pubmed.ncbi.nlm.nih.gov/38112006/
Breast cancer is the most common cancer in women, and luminal breast cancer is the predominant subtype, characterized by the presence of estrogen receptors and/or progesterone receptors in tumor cells....
Adjuvant ET is the pivotal approach in the management of luminal early breast cancer. Hence, new therapeutic approaches have been studied during the last few years, especially in patients with high risk of recurrence.
Open-Label, Phase II, Multicenter Study of Lasofoxifene Plus Abemaciclib for Treating Women With Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation After Disease Progression on Prior Therapies: ELAINE 2
Source : https://pubmed.ncbi.nlm.nih.gov/38072513/
Lasofoxifene plus abemaciclib had an acceptable safety profile, was well tolerated, and exhibited meaningful antitumor activity in women with ESR1-mutated, ER+/HER2- mBC after disease progression on prior CDK4/6i. Observed decreases...
Lasofoxifene plus abemaciclib led to meaningful PFS, ORR, and CBR in ESR1-mutant mBC. Lasofoxifene plus abemaciclib was active for ESR1-mutated breast tumors that progressed with ET and CDK4/6 inhibitors.